Mizuho analyst Salim Syed raised the firm’s price target on Atara Biotherapeutics (ATRA) to $140 from $131 and keeps an Outperform rating on the shares. The firm said it raised its price target on decreased operating expense, adding that it is watching the January 10, 2026 PDUFFA date for tab-cel and any word on the company’s strategic alternatives valuation.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ATRA:
- Potential FDA Approval of Atara’s Tab-cel Therapy: A Game-Changer for Future Growth and CAR T Program Revitalization
- Atara Biotherapeutics reports Q3 EPS (32c), consensus (67c)
- Atara Biotherapeutics reduces workforce by 29%
- Pierre Fabre announces transfer of BLA for tabelecleucel from Atara Biotherapeutics
- Atara Biotherapeutics Announces Significant Workforce Reduction